HS-10234

DRUG2 trials

Sponsors

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Conditions

Chronic HBV InfectionHealthy Subjects

Phase 1

Evaluation of Drug Interaction Between HS-10234 and Emtriccitabine

CompletedNCT04477096

Jiangsu Hansoh Pharmaceutical Co., Ltd.Healthy Subjects

Start: 2020-08-03End: 2020-09-24Updated: 2020-10-01

Phase 3

Study of the Efficacy and Safety of HS-10234 in Patients With Chronic Hepatitis B Virus Infection

CompletedNCT03903796

Jiangsu Hansoh Pharmaceutical Co., Ltd.Chronic HBV Infection

Start: 2018-08-16End: 2024-06-07Updated: 2024-12-17

Related Papers

[Efficacy evaluation of extending or switching to tenofovir amibufenamide in patients with chronic hepatitis B: a phase Ⅲ randomized controlled study].

PubMed2024-10-201 citations

[Safety profile of tenofovir amibufenamide therapy extension or switching in patients with chronic hepatitis B: a phase Ⅲ multicenter, randomized controlled trial].

PubMed2024-10-201 citations

96-Week Treatment of Tenofovir Amibufenamide and Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients

Journal of Clinical and Translational Hepatology2022-11-0121 citations

Study on Pharmacokinetic Interactions Between HS-10234 and Emtricitabine in Healthy Subjects: An Open-Label, Two-Sequence, Self-Controlled Phase I Trial.

2021-10-301 citations

Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B

Alimentary Pharmacology & Therapeutics2021-09-2935 citations